Target intelligence / Profile preview

RPS21 divergent transcript (RPS21-DT)

Target
RPS21-DT
Molecular classification
Other, long non-coding RNA [lncRNA], divergent transcript
01

Overview

RPS21-DT (RPS21 divergent transcript) is classified as a long non-coding RNA (lncRNA) transcribed divergently from the promoter region of the protein-coding RPS21 gene. Divergent transcription is a common phenomenon in mammalian genomes, with many lncRNAs transcribed antisense to nearby protein-coding genes. These divergent lncRNAs are often associated with genes involved in transcriptional regulation and development, potentially playing roles in fine-tuning gene expression. As a non-coding RNA, RPS21-DT does not encode a functional protein and is not recognized as a canonical therapeutic target (e.g., receptor, enzyme, transporter). Its molecular function and clinical significance remain largely uncharacterized, and it is not currently associated with particular drugs, disease roles, or biomarker status. If structured information is required, this would return a null or “not a target” entry for most database fields describing traditional drug targets. RPS21-DT is not misspelled or otherwise incorrect, but inclusion as a target is only appropriate in studies of non-coding RNA function or regulation.

Other names
AL121832.2RPS21-DT
02

Biological functions

Gene expression regulationdivergent transcription from promoter regionsputatively involved in transcriptional regulation
03

Disease associations

Otherno well-established direct disease association for RPS21-DT specificallydivergent transcripts in general are associated with developmental regulation and sometimes cancers

Beyond the preview

Go deeper on RPS21 divergent transcript (RPS21-DT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RPS21 divergent transcript (RPS21-DT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call